Baker Bros. Advisors’s Scribe Therapeutics SCTX Stock Holding History
Bought
Maintained
Sold
Other funds holding SCTX
Baker Bros. Advisors's SCTX Position: Q3 2026 in Review
Baker Bros. Advisors opened a new position in Scribe Therapeutics (SCTX) in Q3 2026: 688,691 shares worth $12.7M. The stake represents 0.06% of the portfolio and ranks #59 among its holdings.
62 funds tracked by Wall St. Rank hold SCTX as of Q3 2026.
- Baker Bros. Advisors held 688,691 shares of Scribe Therapeutics worth $12.7M as of Q3 2026.
- Scribe Therapeutics was a new Baker Bros. Advisors position in Q3 2026.
- Scribe Therapeutics made up 0.06% of Baker Bros. Advisors's portfolio in Q3 2026, its #59 holding.
- 62 funds tracked by Wall St. Rank held Scribe Therapeutics as of Q3 2026.
Based on Baker Bros. Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.